weekly biotechnology news wrap up

June 16, 2017

June 16, 2017

This week’s headlines include: Supreme Court speeds copycat biologic drugs to market, Korean biotech Orum raises $8M for cell-penetrating antibody tech, JSR to Acquire Selexis and Combine Cell Line Specialist with CDMO KBI Biopharma, Sanofi-Regeneron’s Praluent cuts cholesterol in Odyssey trials, Irvine Scientific says it will build a media R&D lab at its Orange County site, and Lilly Acquires DACRA Pipeline from KeyBioScience, with Diabetes Treatments in Mind.


Headlines:

“Supreme Court speeds copycat biologic drugs to market,” Reuters

“The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies…”

“Korean biotech Orum raises $8M for cell-penetrating antibody tech,” Fierce Biotech

Orum Therapeutics has raised a small series A to help push on with its work on a monoclonal antibody designed to treat undruggable cytosolic targets. The Daejeon, South Korea-based biotech has gained $8 million all told, with the money coming from InterVest, KB Investment/Solidus Investment, and LB Investment.

“JSR to Acquire Selexis and Combine Cell Line Specialist with CDMO KBI Biopharma,” Genetic Engineering News

“JSR Life Sciences is to acquire mammalian cell-line development specialist Selexis, and integrate the Switzerland-based company with KBI Biopharma, the U.S.-based biopharma contract development and manufacturing organization (CDMO) that Japan-based JSR acquired in 2015…”

“Sanofi-Regeneron’s Praluent cuts cholesterol in Odyssey trials,” Reuters

“France’s Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol…”

“Irvine Scientific says it will build a media R&D lab at its Orange County site,” BioPharma-reporter

“Irvine Scientific has announced plans for an R&D centre at its site in Irvine, California citing increasing biopharma industry demand for cell culture and media regents…”

“Lilly Acquires DACRA Pipeline from KeyBioScience, with Diabetes Treatments in Mind,” Genetic Engineering News

“Eli Lilly will acquire worldwide rights from KeyBioscience to develop and commercialize its pipeline of dual amylin calcitonin receptor agonists (DACRAs) for type 2 diabetes and other metabolic disorders, the companies said today…”

SUMMARY

Continuous multi-column chromatography (MCC) has been gaining increasing interest as an enabling bioprocessing technique that allows for increases in specific productivity (g/L/hr) and operating binding capacity (g mAb/L sorbent) over traditional batch solutions. With recent advances, users have reported an increase in cost savings stemming from reduced resin volumes, lower buffer consumption, and increased resin usage.

Mark Pagkaliwangan presents on July 18th at 1PM EDT, with David Johnson moderating, as they discuss MCC solution advances with processes utilizing two columns or more. They will explore how the total number of columns used in a process can affect performance, and how titer and flowrate can be optimized with more columns for greater efficiency and productivity.

Registration for the Americas
Registration for Europe/Asia

Cell Culture Events:

Cell Culture & Cell Therapy: Bioprocessing Conference – June 26-27, 2017, Philadelphia

MarketsandMarkets put together a unique platform to establish the reproducible and robust manufacturing processes for the production of stable cell culture and therapeutic cells. At the Cell Culture & Cell Therapy: Bioprocessing Conference scheduled to be held in Philadelphia, USA on 26 – 27 June 2017, leading experts in the industry will be gathered to discuss strategies, technologies and innovations in the area of bioprocessing of cell culture and cell-gene therapies.